Form 8-K · Current Report · Filed 2025-06-23
BridgeBio Pharma, Inc. Shareholders Approve Officer Exculpation Amendment
On June 20, 2025, BridgeBio Pharma, Inc. held its Annual Meeting of Stockholders, where shareholders approved several key proposals. The most significant approval was the Officer Exculpation Amendment to the Company's Amended and Restated Certificate of Incorporation, which limits the liability of certain officers as permitted under Delaware law. Other approvals included the election of directors, a non-binding advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and an amendment to the 2021 Stock Option and Incentive Plan to increase the number of shares reserved for issuance. The meeting also approved an adjournment if any proposal failed to receive sufficient votes.
- Filer
- BridgeBio Pharma Inc. BBIO · NASDAQ
- Filed
- Accession
- 0001140361-25-023362
- CIK
- 0001743881
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Material Modification to Rights of Security Holders
Amendments to Articles of Incorporation or Bylaws
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$41.73
Next session
+6.5%
Since filing
+91.9%
Latest close
$80.09
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BBIO reporting the same item, with the next session's move:
Exhibits (2)
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Never miss another BBIO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.